CalciMedica NASDAQ: CALC www.calcimedica.com
NASDAQ: CALCLa Jolla, US · Founded 2011 · 5 known investors
Find your way into CalciMedica NASDAQ: CALC www.calcimedica.com
97 people in our graph share verified history with the CalciMedica NASDAQ: CALC www.calcimedica.com team — schools, employers, funds. One of them is your warm intro.
Tom Stephensonunlockedknows Sudarshan Hebbar · together at University of Chicago (overlapped)
×6knows the team · via University of Chicago
×2knows the team · via The Johns Hopkins University
×2knows the team · via Tulane University School of Medicine
knows the team · via Oncimmune
CalciMedica is a clinical-stage biopharmaceutical company developing CRAC (calcium release-activated calcium) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases. Its drug candidates target conditions such as acute pancreatitis, acute kidney injury, and pulmonary arterial hypertension.
Founders & leadership
CalciMedica NASDAQ: CALC www.calcimedica.com was founded in 2011 by Kenneth A. Stauderman and Gonul Velicelebi.
KA
GV
Gonul VelicelebiCo-founder
DG
Daniel GeffkenExecutive
AR
A. Rachel LehenyExecutive
MJ
SB
Stephen BardininChief Financial Officer
SH
Sudarshan HebbarinChief Medical OfficerSudarshan Hebbar is Chief Medical Officer at CalciMedica, a clinical-stage biopharmaceutical company developing therapies targeting calcium signaling pathways for inflammatory and immunologic diseases. He has over a decade of experience in nephrology and critical care medicine, along with extensive involvement in clinical and product development for diagnostics and therapeutics.
AC
Andrew CunninghaminExecutive
MO
MICHAEL O'ROURKEExecutive
JH
JUSTIN HANESExecutive
Board
FM
EB
Eric BjerkholtBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$142.7M disclosed across 6 rounds · 2014–2023
▶$9.1MraisedApr 2023 · 55 investors · BiotechnologyRule 506(b)
▶$9.1MraisedApr 2023 · 55 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric W. RobertsExecutive Officer, Director
- Daniel GeffkenExecutive Officer
- A. Rachel LehenyExecutive Officer, Director
- Kenneth A. StaudermanExecutive Officer
- Sudarshan HebbarExecutive Officer
- Eric BjerkholtDirector
- Frederic GuerardDirector
- Robert N. WilsonDirector
- Fred MiddletonDirector
- Michael J. DunnExecutive Officer
- Allan ShawDirector
- Offering amount
- $9.1M
- Amount sold
- $9.1M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$55MraisedAug 2019 · 8 investors · PharmaceuticalsRule 506(b)
▶$55MraisedAug 2019 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gerald Cagle, Ph.D.Director
- Chau KhuongDirector
- Emmett Cunningham, M.D., Ph.D.Director
- Christy Shaffer, Ph.D.Director
- Cameron Wheeler, Ph.D.Director
- Hansoo Michael KeyoungDirector
- Pamela WapnickExecutive Officer, Promoter
- Frederic GuerardExecutive Officer, Director, Promoter
- Offering amount
- $80M
- Amount sold
- $55M
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$75.4MraisedJun 2018 · 16 investors · BiotechnologyRule 506(b)
▶$75.4MraisedJun 2018 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gerald CagleDirector
- Chau KhoungDirector
- Christy ShafferDirector
- Cameron WheelerDirector
- Emmett CunninghamDirector
- Justin HanesDirector
- Jeffrey ClelandExecutive Officer, Director
- Offering amount
- $80.4M
- Amount sold
- $75.4M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$750KraisedDec 2015 · 1 investors · BiotechnologyRule 506(b)
▶$750KraisedDec 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gerald CagleDirector
- Christy ShafferExecutive Officer, Director
- Jeffrey ClelandExecutive Officer, Director
- Justin HanesDirector
- Offering amount
- $1M
- Amount sold
- $750K
- Proceeds to insiders
- $35K
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$1.7MraisedMar 2015 · 2 investors · BiotechnologyRule 506(b)
▶$1.7MraisedMar 2015 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael O'RourkeExecutive Officer, Director
- Justin HanesDirector
- Gerald CagleDirector
- Jeffrey ClelandDirector
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- Minimum investment
- $240K
- Proceeds to insiders
- $100K
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$750KraisedOct 2014 · 3 investors · BiotechnologyRule 506(b)
▶$750KraisedOct 2014 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JEFFREY CLELANDDirector
- GERALD CAGLEDirector
- MICHAEL O'ROURKEExecutive Officer, Director
- JUSTIN HANESExecutive Officer, Director
- Offering amount
- $1.3M
- Amount sold
- $750K
- First sale
- Aug 2014
- Incorporated
- Limited Liability Company, Maryland, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$321.5Mvaluation at IPOSep 2020 · $16.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does CalciMedica NASDAQ: CALC www.calcimedica.com do?
- CalciMedica is a clinical-stage biopharmaceutical company developing CRAC (calcium release-activated calcium) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases. Its drug candidates target conditions such as acute pancreatitis, acute kidney injury, and pulmonary arterial hypertension.
- Who founded CalciMedica NASDAQ: CALC www.calcimedica.com?
- CalciMedica NASDAQ: CALC www.calcimedica.com was founded by Kenneth A. Stauderman, Gonul Velicelebi in 2011.
- Who are CalciMedica NASDAQ: CALC www.calcimedica.com's investors?
- CalciMedica NASDAQ: CALC www.calcimedica.com's investors include Aisling Capital, Sanderling Ventures, Clarus, Clarus Lifesciences, OrbiMed.
- How much funding has CalciMedica NASDAQ: CALC www.calcimedica.com raised?
- CalciMedica NASDAQ: CALC www.calcimedica.com has disclosed $142.7M raised across 6 rounds.
- Where is CalciMedica NASDAQ: CALC www.calcimedica.com headquartered?
- CalciMedica NASDAQ: CALC www.calcimedica.com is headquartered in La Jolla, US.